RxDoctor Payments Data

Emily Nehme, PA

Medical · Allentown, PANPI 1689196974

Payments from drug & device makers

$9,900in general payments, 2019–2025

Across 306 payments — averaging $32.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$3K
  • Madrigal Pharmaceuticals$897
  • Johnson & Johnson$548
  • E.r. Squibb & Sons, L.L.C.$506
  • Pfizer$476
  • Sanofi$471
  • plus $4K from 25 others

What the payments were for

  • Food & beverage$9,74298%
  • Education$1592%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$9,900 in reported general payments places this provider in the 95th percentile of 2,594 medical providers in Pennsylvania.

See all medical providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$82,698
Medicare patients
605
Services billed
992

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
CreonLipase/Protease/Amylase51$247,074
LinzessLinaclotide57$61,879
XifaxanRifaximin19$44,178
Mesalamine38$30,455
Lubiprostone39$9,519
Dexlansoprazole DrDexlansoprazole21$6,220
Pantoprazole Sodium318$6,145
Colestipol Hcl41$4,202
Famotidine211$3,967
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates53$3,127
Esomeprazole Magnesium39$2,689
SutabSod Sulf/Pot Chloride/Mag Sulf16$2,549
Omeprazole112$1,587
Gavilyte-CPeg3350/Sod Sulf,bicarb,cl/Kcl56$895
Dicyclomine Hcl42$732

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AbbVieCreon, Linzess$3,197$308,953108 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$400$44,17819 claims
Braintree Laboratories, Inc.Sutab$108$2,54916 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 2,594 medical providers in Pennsylvania.

Other medical in Allentown

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →